Amid Regulatory and Reimbursement Difficulties, Some Encouraging Advancements for Personalized Rx

This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
      Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter.